Risk of venous thromboembolism associated with lupus anticoagulant, anticardiolipin antibodies, factor V Leiden and the prothrombin G20210A mutation, either alone or in combinations
. | No defects, n = 115 . | Single defect, n = 22 . | Two defects, n = 7 . |
|---|---|---|---|
| Patients with VTE, n | 6 | 6 | 3 |
| Observation period, total y | 1479 | 299 | 98 |
| Annual incidence, % (95% CI) | 0.41 (0.15-0.88) | 2.01 (0.74-4.37) | 3.05 (0.63-8.93) |
| Relative risk (95% CI) | 1 | 5.10 (1.64-15.86) | 8.20 (2.04-32.9) |
| P | — | .005* | .003* |
. | No defects, n = 115 . | Single defect, n = 22 . | Two defects, n = 7 . |
|---|---|---|---|
| Patients with VTE, n | 6 | 6 | 3 |
| Observation period, total y | 1479 | 299 | 98 |
| Annual incidence, % (95% CI) | 0.41 (0.15-0.88) | 2.01 (0.74-4.37) | 3.05 (0.63-8.93) |
| Relative risk (95% CI) | 1 | 5.10 (1.64-15.86) | 8.20 (2.04-32.9) |
| P | — | .005* | .003* |
— indicates not applicable.
Compared with no defects.